Results: 8
Cost-Effectiveness Analyses in Multiple Sclerosis: A Review of Modelling Approaches.
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 6, p. 559, doi. 10.1007/s40273-014-0150-1
- By:
- Publication type:
- Article
Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation.
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 6, p. 601, doi. 10.1007/s40273-014-0152-z
- By:
- Publication type:
- Article
Modelling Technique, Structural Assumptions, Input Parameter Values: Which Has the Most Impact on the Results of a Cost-Effectiveness Analysis?
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 6, p. 521, doi. 10.1007/s40273-014-0157-7
- By:
- Publication type:
- Article
Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines.
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 6, p. 525, doi. 10.1007/s40273-014-0162-x
- By:
- Publication type:
- Article
Methods for Adjusting for Bias Due to Crossover in Oncology Trials.
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 6, p. 533, doi. 10.1007/s40273-014-0145-y
- By:
- Publication type:
- Article
When to Use Discrete Event Simulation (DES) for the Economic Evaluation of Health Technologies? A Review and Critique of the Costs and Benefits of DES.
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 6, p. 547, doi. 10.1007/s40273-014-0147-9
- By:
- Publication type:
- Article
Using the EuroQol EQ-5D in Swiss Cancer Patients, Which Value Set Should be Applied?
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 6, p. 591, doi. 10.1007/s40273-014-0151-0
- By:
- Publication type:
- Article
Cost Effectiveness of a Pharmacist-Led Information Technology Intervention for Reducing Rates of Clinically Important Errors in Medicines Management in General Practices (PINCER).
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 6, p. 573, doi. 10.1007/s40273-014-0148-8
- By:
- Publication type:
- Article